Albert Rizzo, MD, FACP, chief medical officer for the American Lung Association, discusses the prevalence of overtreatment and undertreatment in chronic obstructive pulmonary disease (COPD).
Albert Rizzo, MD, FACP, chief medical officer for the American Lung Association, discusses the prevalence of overtreatment and undertreatment in chronic obstructive pulmonary disease (COPD).
Transcript
How prevalent is overtreatment in COPD? Are there identified ways to mitigate this?
I think the main reason some overtreatment may occur is when the symptom of shortness of breath is thought to be COPD and it’s not. Certainly, very often, cardiac disease can make an individual short of breath and it’s not always clear cut whether it’s heart or lungs causing the problem. It’s been, over the years, the pulmonologists say it’s the heart, the heart doctors will say it’s the lungs, so it can be both. Comorbidities exist in COPD. But overtreatment can include giving the patient of the drugs.
Maybe an individual does not need an inhaled steroid, all they need is the bronchodilators. That would be an individual who has symptoms but really has not had risk of exacerbation. So, overtreatment with inhaled corticosteroids could be a concern if that happens. It’s hard to quantify how much that’s happened over the years because there’s been a little change in the guidelines as to the role of inhaled corticosteroids and when’s the proper time to institute them.
But in general, COPD has probably been a bit undertreated over the years. Initially it started out at giving them 1 maybe short-acting bronchodilator they would use intermittently. If you think about the C in COPD, it stands for chronic. It means there’s always airflow obstruction. So, a patient diagnosed with COPD needs bronchodilation on an ongoing basis most of the time. We now know that bronchodilatation can be maximized by using 2 pathways: long-acting beta agonists and the long-acting antimuscarinic. So many individuals now would say that the first diagnosis of COPD may mean an individual be put on a dual bronchodilator, and I think a lot of people are still on either single or intermittent use of bronchodilators and I would think that’s an undertreatment.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Study: Decreased BMI Increases Severe Exacerbation, All-Cause Mortality Risk in Patients With COPD
April 10th 2024Decreased body mass index (BMI) in patients with chronic obstructive pulmonary disease (COPD) was linked to a higher risk of severe exacerbations and all-cause mortality, emphasizing the importance of monitoring BMI for managing COPD and predicting outcomes.
Read More
Study: 1 in 6 US Patients With COPD Suffer From Cost-Related Medication Nonadherence
April 3rd 2024Medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) is associated with increasing COPD symptoms, hospitalizations, morbidity, mortality, and health care expenditures.
Read More